Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations
Early dose-escalation data from Phase…Read More
You might also be interested in reading China’s Aurora Mobile soars over 200% after adding DeepSeek AI model on platform.